Pharmacogenomics: will we still need cost-effectiveness evaluations? Comment 11 February 2013 Pages: 2 - 2
Infliximab for Crohn's disease perianal fistulae worth its cost? Clinical study 11 February 2013 Pages: 3 - 3
NSCLC: paclitaxel + carboplatin more costly than vinorelbine + cisplatin Clinical study 11 February 2013 Pages: 4 - 4
Adjuvant chemotherapy use in colon cancer declines with age Clinical study 11 February 2013 Pages: 5 - 5
Allergic conjunctivitis: improved QOL with olopatadine plus loratadine Clinical study 11 February 2013 Pages: 6 - 6
Antihyperlipidaemics cost effective in 1° prevention of CHD? Clinical study 11 February 2013 Pages: 6 - 6
Using QOL data as a proxy measure of utility in economic analyses Clinical study 11 February 2013 Pages: 7 - 7
